The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
Recruiting
Phase 1
Interventional Study
Obesity
At a Glance
- Age
- 50 – 70
- Sex
- Female
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 144 (estimated)
- Sponsor
- Novo Nordisk A/S · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
In this study we will investigate how the medicine cagrilintide affects bone health in women after menopause with obesity during weight loss, compared to treatment with placebo (the dummy medicine with no active substances) and semaglutide. The purpose is to examine whether cagrilintide can reduce the decline in bone mass associated to weight loss. Participants will either get cagrilintide, semagl…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion criteria
* Female.
* Post-menopausal at screening (defined as minimum 12 months of amenorrhea, high levels of follicular stimulating hormone (FSH) 16 - 130 international units per liter (IU/L), and low levels of anti-müllerian hormone (AMH) and inhibin B).
* Age 50-70 years (both inclusiv…
Contacts